... to be accretive to earnings beginning in 2010. Under the terms of the deal, Bristol-Myers shareholders can exchange some, none or all of their shares of the company for shares of Mead Johnson ... taking meaningful steps to prepare for the loss of exclusivity of Plavix. Currently, we are Neutral on Bristol-Myers. Zacks Investment Research ($BMY) Bristol-Myers Squibb Divests its Nutritional Segment

Title: Bristol-Myers Squibb Pharmaceuticals Ltd, R (on the application of) v National Institute for Health and Clinical Excellence The Skinny: Challenges of the decision of the defendant, the National Institute for Health and Clinical Excellence (NICE) refusing to recommend the use of abatacept (ABA) for treatment in connection with rheumatoid arthritis in the National Health ...

By Mike Paulenoff Earlier this week, Bristol-Myers Squibb emerged to the upside from a two-year base-like accumulation pattern when the price structure hurdled and sustained above 23.80-24.00. Since then (Mon morning), BMY has consolidated above its breakout plateau, which I consider to be a very constructive technical sign—that higher prices should ...

... that’s Huet in the picture). At the time Huet arrived, Bristol-Myers was emerging from the loss of its former chief executive, Peter Dolan, ... Huet’s arrival was seen by some Wall Streeters as a signal that Cornelius and the Bristol-Myers board would shop the drugmaker, a suspicion that hasn’t gone away. His departure is unlikely to alter that sentiment. In any event, Huet is being ...

I decided to close this position early, as Bristol Myers was substantially above the $22 strike price of the CC. I had entered this position as a way to continue a similar annualized return to the position I had held in COP which was called away pre-ex-dividend date. As there was essentially no time value remaining in the CC, I closed the ...

Biopharmaceutical company Bristol-Myers Squibb (BMY) is performing on schedule, which is why I'm reiterating my buy rating for the company's shares, first recommended on June 1, 2009 at ... are $2.02 to $2.21. Continue reading Bristol-Myers Squibb is in an uptrend Bristol-Myers Squibb is in an uptrend originally appeared on BloggingStocks on Thu, 03 Dec ...

My near-term work argues strongly that Bristol-Myers Squibb (NYSE: BMY) is nearing the completion of its corrective period off of last week’s high at 25.75 into the 24.50 area. Right now I cannot rule out another loop down to revisit 24.50 (last Friday’s low), but if further weakness emerges I will want to enter/add to long ...

... - Mead Johnson Nutrition Co. – Over the weekend Bristol Myers Squibb decided to sell its remaining 83% stake ... to 56.3% as investors wonder whether the company will be able to stand on its own two feet without Bristol Myers. One option trader who clearly knows the stock well ... . The investor thus expects the share price to rise should Bristol find a buyer and similarly expects lower volatility. ...

Ken Caruso/a> submits: I was reading this Fat Pitch Financials post and saw mention of Bristol Myers Squibb (BMY) offering their remaining ownership of Mead Johnson Nutrition (MJN) in exchange for BMY shares. Bristol Myers did a public offering of MJN earlier this year ... since then. Mead Johnson was started in 1905 and acquired by Bristol Myers in the 1960s. Complete Story »

Bristol-Myers Splits Off Mead Johnson Nutrition Posted: 7:42 pm EST November 15, 2009Updated: 9:15 pm EST November 15, 2009 NEW YORK -- Bristol-Myers Squibb Co. is splitting off its holdings in infant formula maker Mead Johnson Nutrition Co. in order to focus on its biopharmaceutical business. via wftv.com Posted via web from Jack's posterous

... 's no secret that Bristol-Myers Squibb has spent the last couple years solidifying its stance as a pure ... ballsy, and we think they're all the more interesting to watch because of it. And we really thought Bristol was onto something interesting when they IPO'd Mead Johnson ... accretive to earnings in 2010 by reducing the number of Bristol's shares outstanding, thus increasing earnings ...

Scientific American Sanofi, Bristol's Plavix Ads May Have Affected Price Bloomberg Nov. 23 (Bloomberg) -- Sanofi-Aventis SA and Bristol-Myers Squibb Co.'s best-selling blood thinner Plavix may have cost US taxpayers hundreds of millions of dollars because of ineffective advertising, research suggests. ... Consumer drug ads drive up ...

Photos from a Bristol-Myers Squibb Alumni Networking/Mentored Undergraduate Summer Experience (MUSE) Poster Session event held December 7, 2009, at Bristol-Myers Squibb’s Lawrenceville Campus. The event was hosted by Bristol-Myers Squibb and the College’s Office of Alumni Affairs.

... on cross-border transactions such as in China and India. Bristol-Myers Squibb Co. (NYSE:BMY) isn't done with deals as it ... including Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) possibly going to Bristol-Myers, Gilead Sciences Inc. (NASDAQ:GILD) or Johnson & Johnson (NYSE:JNJ). Oncology is ... (NASDAQ:CRGN) for $94.5 million.Bristol-Myers Squibb came away with Medarex Inc. (NASDAQ:MEDX) for $2.4 ...

... Stock Alerts From Stock-PR.com Stock-PR Monday November 23, 2009 Watch List!     Bristol-Myers Squibb Co. (BMY) Bristol-Myers Squibb Company (BMS) engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of pharmaceuticals and nutritional products worldwide. ...